



## NCL Method STE-1.2

# Detection and Quantification of Gram-Negative Bacterial Endotoxin Contamination in Nanoparticle Formulations Using the Kinetic Turbidity LAL Assay

**Nanotechnology Characterization Laboratory**  
Frederick National Laboratory for Cancer Research  
Leidos Biomedical Research, Inc.  
Frederick, MD 21702  
(301) 846-6939  
[ncl@mail.nih.gov](mailto:ncl@mail.nih.gov)  
<https://ncl.cancer.gov>



This protocol assumes an intermediate level of scientific competency with regard to techniques, instrumentation, and safety procedures. Rudimentary assay details have been omitted for the sake of brevity.

Method written by:

Barry W. Neun

Marina A. Dobrovolskaia \*

Nanotechnology Characterization Lab, Cancer Research Technology Program, Frederick  
National Laboratory for Cancer Research sponsored by the National Cancer Institute, Frederick,  
MD 21702

\*- address correspondence to: [marina@mail.nih.gov](mailto:marina@mail.nih.gov)

**Protocol adapted from:**

Neun, B. W. and Dobrovolskaia, M. A., Detection and quantitative evaluation of endotoxin contamination in nanoparticle formulations by LAL-based assays, in *Characterization of nanoparticles intended for drug delivery*, S. McNeil, Editor. **2011**, Humana Press. p. 121-130. doi: 10.1007/978-1-60327-198-1\_12

**Please cite this protocol as:**

Neun BW, Dobrovolskaia MA, NCL Method STE-1.2: Detection and Quantification of Gram-Negative Bacterial Endotoxin Contamination in Nanoparticle Formulations by Kinetic Turbidity LAL Assay. <https://ncl.cancer.gov/resources/assay-cascade-protocols> DOI: 10.17917/RK6R-P820

## 1. Introduction

This document describes a protocol for a quantitative detection of Gram-negative bacterial endotoxin in nanoparticle preparations using a kinetic turbidity Limulus Amebocyte Lysate (LAL) assay. The protocol is based on the USP standard 85 “Bacterial endotoxin test” [1].

## 2. Principles

Gram negative bacterial endotoxin catalyzes the activation of proenzyme in the Limulus Amebocyte Lysate. In the presence of endotoxin, LAL becomes turbid. The time taken to reach a particular level of turbidity (the onset time) is determined. Higher endotoxin concentrations give shorter onset times. The concentration of endotoxin in a sample is in direct proportion with onset time and is calculated from a standard curve prepared by spiking known concentrations of endotoxin standard into LAL grade water. This method relies on PyrosKinetix and PyrosKinetixFlex instrument by the Associates of Cape Cod Inc. (ACC). Data analysis is performed using PyrosEQS software (ACC).

## 3. Reagents, Materials, and Equipment

*Note: The NCL does not endorse any of the suppliers listed below; these reagents were used in the development of the protocol and their inclusion is for informational purposes only. Equivalent supplies from alternate vendors can be substituted. Please note that suppliers may undergo a name change due to a variety of factors. Brands and part numbers typically remain consistent but may also change over time.*

- 3.1 Reagents
  - 3.1.1 Test nanomaterial
  - 3.1.2 Sodium Hydroxide (NaOH) (Sigma, S2770)
  - 3.1.3 Hydrochloric acid (HCl) (Sigma, H9892)
  - 3.1.4 Control Endotoxin Standard (ACC, E0005)
  - 3.1.5 LAL Reagent (ACC, T0051)
  - 3.1.6 LAL grade water (ACC, WP0501)
  - 3.1.7 Glucashield buffer (ACC, GB051-25)

- 3.2 Materials
  - 3.2.1 Pyrogen-free pipettes and tips, 0.05 to 10 mL (RAININ)
  - 3.2.2 Pyrogen-free microcentrifuge tubes, 1.5 mL
  - 3.2.3 Repeat pipettor
  - 3.2.4 Combitip, 5mL pyrogen free
  - 3.2.5 Disposable endotoxin-free glass dilution tubes, 12x75 mm (ACC, TB240)
  - 3.2.6 Disposable endotoxin-free reaction tubes, 8 x75 mm (ACC, TK100)
- 3.3 Equipment
  - 3.3.1 Microcentrifuge
  - 3.3.2 Refrigerator, 2-8°C
  - 3.3.3 Freezer, -20°C
  - 3.3.4 Vortex
  - 3.3.5 Pyros Kinetix or PyrosFlex Instrument, ACC

#### 4. Reagent Preparation

##### 4.1 Sodium Hydroxide

Prepare from concentrated stock by dilution into pyrogen-free LAL reagent water to make a 0.1 N final concentration solution.

##### 4.2 Hydrochloric Acid

Prepare from concentrated stock by dilution into pyrogen-free LAL reagent water to make a 0.1 N final concentration solution.

##### 4.3 Control Standard Endotoxin (CSE)

*E. coli* lipopolysaccharide (LPS) supplied by ACC is a USP certified control standard endotoxin (CSE) provided as a lyophilized powder. The contents of the vial containing CSE should be reconstituted with ~3.5 - 5.0 mL of pyrogen-free LAL reagent water, depending on the potency. The final concentration of this stock solution should be calculated for each lot and depends on product potency and amount supplied in each vial. The information about product potency and amount per vial can be found on the enclosed certificate of analysis supplied with each endotoxin standard. During reconstitution and prior to use, the stock solution should be vortexed vigorously for 30-60 sec, with 5-10 min settling times, over a

30-60 min time frame, and allowed to equilibrate to room temperature prior to use. Reconstituted endotoxin standard is stable for 4 weeks when stored at 2-8°C.

#### 4.4 LAL Reagent

LAL reagent is provided as lyophilized powder. The contents of each vial should be reconstituted per manufacturer’s recommendations and can be done in water or in Glucashield buffer. The NCL preferred method is Glucashield buffer, which allows for exclusion of interference from beta-glucans, a very common in nanomaterials produced using filtration steps. Most vials will require reconstitution to a final volume of 5 mL.

### 5. Preparation of Standard Curve and Quality Controls

#### 5.1 Calibration Standards

| <b>Sample</b> | <b>Nominal Concentration (EU/mL)</b> | <b>Preparation Procedure</b>             |
|---------------|--------------------------------------|--|
| Int. A        | 100*                                 | 100 µL Stock + 900 µL LAL reagent water  |
| Int. B        | 10                                   | 100 µL Int. A + 900 µL LAL reagent water |
| Cal. 1        | 1.0                                  | 100 µL Int. B + 900 µL LAL reagent water |
| Cal. 2        | 0.1                                  | 100 µL Cal. 1 + 900 µL LAL reagent water |
| Cal. 3        | 0.01                                 | 100 µL Cal. 2 + 900 µL LAL reagent water |
| Cal. 4        | 0.001                                | 100 µL Cal. 3 + 900 µL LAL reagent water |

\* This is provided only as an example. Dilution of the CSE to make Int. and Cal. solutions depends on the concentration of the CSE stock and is determined for each lot of CSE reagent. Numbers shown in the table above are calculated based on a stock concentration of 1000 EU/mL.

## 5.2 Preparation of Quality Controls

| <b>Sample</b> | <b>Nominal Concentration<br/>(EU/mL)</b> | <b>Preparation Procedure</b>             |
|---------------|--|--|
| Int. A*       | 100**                                    | 100 µL Stock + 900 µL LAL reagent water  |
| Int. B*       | 10**                                     | 100 µL Int. A + 900 µL LAL reagent water |
| Int. C*       | 1.0**                                    | 100 µL Int. B + 900 µL LAL reagent water |
| QC1           | 0.05                                     | 50 µL Int. C + 950 µL LAL reagent water  |

\* Although concentrations of these solutions match ones for Int. A, B and Cal 1 in Section 5.1, it is not good practice to prepare calibrators and quality controls from the same intermediates.

\*\* Intermediate solutions A, B, C are prepared only to make QC1 and are not used in the assay.

## 5.3 Preparation of Inhibition/Enhancement Control

| <b>Sample</b> | <b>Nominal Concentration<br/>(EU/mL)</b> | <b>Preparation Procedure</b>                              |
|---------------|--|---|
| Int. A*       | 100**                                    | 100 µL Stock + 900 µL LAL reagent water                   |
| Int. B*       | 10**                                     | 100 µL Int. A + 900 µL LAL reagent water                  |
| Int. C*       | 1.0**                                    | 100 µL Int. B + 900 µL LAL reagent water                  |
| IEC           | 0.05                                     | 25 µL Int. C + 475 µL nanoparticle solution/suspension*** |

\* Although concentrations of these solutions match ones for Int. A, B and Cal 1 in Section 5.1, it is not a good practice to prepare calibrators and quality controls from the same intermediates.

\*\* Intermediate solutions A, B, C are prepared only to make IEC and are not used in the assay.

\*\*\* The concentration of nanoparticles should be equal to those assayed for the test-sample. You will need to prepare IEC for each dilution of the nanomaterial assayed in this test.

## 6. Preparation of Study Samples

Study samples should be reconstituted in either LAL reagent water or sterile, pyrogen-free PBS. The pH of the study sample should be checked using a pH microelectrode and adjusted, if necessary, within the range of 6.0-8.0 using either sterile NaOH or HCl. Do not adjust the pH of unbuffered solutions. To avoid sample contamination from microelectrode, always remove a small aliquot of the sample for use in measuring the pH. If the sample was prepared in PBS, blank PBS should also be tested in the assay.

The concentration of nanomaterial is unique to each formulation. The goal of this test is to measure endotoxin level per mg of the test formulation, which commonly refers to the active pharmaceutical ingredient (API) but may also be measured in mg of total formulation or total element (e.g. gold or silver). The sample should be tested from the stock using several dilutions not exceeding the Maximum Valid Dilution (MVD).

To determine the MVD one needs to know three parameters: endotoxin limit (EL), sample concentration and assay sensitivity ( $\lambda$ ). EL is calculated according to the following formula:

$$EL=K/M$$

where K is maximum endotoxin level allowed per dose (5 EU/kg for all routes of administration except for the intrathecal route, for which K is 0.2 EU/kg) and M is the maximum dose to be administered per kg of body weight per single hour [1]. Note, estimation of EL for nanomaterials used as radiopharmaceuticals or as medical devices will be different; please refer to USP BET 85 for details [1]. When the dose information for the test nanomaterial is available based on an animal model (e.g. in mouse), one may use it to convert into human equivalent dose (HED). To do so, the animal dose is divided by the conversion factor specific to each animal species, e.g. 12.3 for mouse. Please refer to the FDA guideline for other conversion ratios [2]. Dose for cancer therapeutics is often provided in  $\text{mg}/\text{m}^2$  instead of  $\text{mg}/\text{kg}$ . To convert an animal or human dose from  $\text{mg}/\text{m}^2$  to  $\text{mg}/\text{kg}$  the dose in  $\text{mg}/\text{kg}$  is divided by the conversion factor of 37, indicated as  $k_m$  (for mass constant). The  $k_m$  factor has units of  $\text{kg}/\text{m}^2$ ; it is equal to the body weight in kg divided by the surface area in  $\text{m}^2$ . Example  $74 \text{ mg}/\text{m}^2 / 37 = 2 \text{ mg}/\text{kg}$  [2].

The MVD is determined according to the following formula:

$$\text{MVD} = (\text{EL} \times \text{sample concentration})/\lambda$$

For example, when nanoparticle sample concentration is 10  $\text{mg}/\text{mL}$  and its maximum dose in mouse is 123  $\text{mg}/\text{kg}$ , the HED is  $123/12.3 = 10 \text{ mg}/\text{kg}$ . The EL for all routes except intrathecal

would be 0.5 EU/mg (5 EU/kg/10mg/kg) and the MVD would be 5000 ((0.5 EU/mg x 10 mg/mL)/0.001EU/mL). In this case, the nanomaterial will be tested directly from stock and at several dilutions not exceeding 5000, e.g. 5, 50, 500 and 5000. When the information about the dose is unknown, the highest final concentration of the test nanomaterial is 1 mg/mL and the MVD is 500. It is very important to recognize that if the dose, route of administration and/or the sample concentration for the test nanomaterial change, the EL and MVD will also change.

**Important:** Turbid nanoformulations will interfere with this assay and therefore should be tested using other versions of LAL (e.g. gel-clot and chromogenic). Turbid formulations with low MVD will likely interfere with both turbidity and chromogenic LAL and should be tested using gel-clot and other methods as discussed in reference 3.

## 7. Experimental Procedure

- 7.1 Turn the instrument on approximately 20-30 minutes before starting the assay to allow the instrument time to warm up. Set the detection wavelength to 660 nm, which is the mode appropriate for the turbidity LAL.
- 7.2 Start PyrosKinetix or PyrosEQS software and create a new experiment template. Make sure instrument-computer communication is not interrupted. Make sure negative control sample is entered through the negative control panel, not through the sample panel, otherwise software will not be able to generate report.
- 7.3 Add 100 µL of negative control (water), calibration standards, quality control, IEC and test nanoparticles into pre-labeled glass tubes. Prepare duplicate tubes for each sample.
- 7.4 Using a repeating pipette, add 100 µL of LAL reagent to first test vial, vortex it briefly, and insert into test slot in the instrument carousel. Repeat this procedure for other samples, processing one sample at a time. Allow instrument to run each point for no less than 7200 sec to allow time for samples with low amounts of endotoxin to develop. If no detectable endotoxin is present in the sample, the software will mark this sample as “not detected by 7200s”.

**Note:** Some lots of the lysate are less sensitive than others, if the sensitivity of the lot is low, the time may need to be adjusted to 9600s or longer in order to allow the lowest calibrator to develop.



## 8. Assay Acceptance Criteria

- 8.1 Linear regression algorithm is used to construct the standard curve. Precision (%CV) of each calibration standard and quality control should be within 25%.
- 8.2 At least three calibration standards should be available for the assay to be considered acceptable.
- 8.3 The correlation coefficient of the standard curve must be at least 0.980.
- 8.4 If quality controls fail to meet acceptance criterion described in 8.1, run should be repeated.
- 8.5 If standard curve fails to meet acceptance criterion described in 8.1-8.3, the run should be repeated.
- 8.6 Precision of the study sample should be within 25%.
- 8.7 Precision of the inhibition/enhancement control should be within 25%.
- 8.8 Spike recovery indicative of the accuracy of the inhibition/enhancement control should be between 50 and 200% [2]. Spike recovery less than 50% is indicative of inhibition; that above 200% is indicative of either endotoxin contamination or enhancement.
- 8.9 If sample interference is detected, the assay results for this sample are invalid. Other tests should be considered as discussed in reference 3.

## 9. Sample Acceptance Criteria

- 9.1 Endotoxin levels in the sample are acceptable if within the EL calculated for the given formulation (please refer to section 6 and reference 3 for details).

## 10. References

1. USP 34-NF29. <85>. Bacterial Endotoxins. Rockville, MD: United States Pharmacopeia, 2011, Volume 1, 78-81.
2. FDA Guidance for Industry and Reviewers Estimating the Safe Starting Dose in Clinical Trials for Therapeutics in Adult Healthy Volunteers. December 2002.
3. US FDA. Guidance for Industry. Pyrogen and Endotoxins testing: Questions and answers, 2012.

## 11. Abbreviations

|      |                                  |
|------|----------------------------------|
| API  | active pharmaceutical ingredient |
| BET  | bacterial endotoxin test         |
| CSE  | control standard endotoxin       |
| CV   | coefficient of variation         |
| EU   | endotoxin unit                   |
| EL   | endotoxin limit                  |
| FDA  | Food and Drug Administration     |
| HCl  | hydrochloric acid                |
| IEC  | inhibition/enhancement control   |
| LAL  | Limulus Amebocyte Lysate         |
| LPS  | lipopolysaccharide               |
| MVD  | maximum valid dilution           |
| NaOH | sodium hydroxide                 |
| PBS  | phosphate buffered saline        |
| USP  | United State Pharmacopeia        |